Complete digital access to quality journalism on any device. Cancel anytime during your trial.
When GlaxoSmithKline (GSK) exited Nigeria in late 2023, it left a major gap in the country’s pharmaceutical supply chain. One of the most affected products was Augmentin, GSK’s well-known brand of amoxicillin and clavulanate potassium. The antibiotic had long been a household name for treating bacterial infections.
Continue reading your article with a BusinessDay subscription
